Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 15

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 15
---
 in a registered direct offering under the Company’s existing shelf registration
statement on Form F-3 (File No. 333-268873).

Merger Transaction

In the second quarter of fiscal 2025, the Company determined that it
would be in its and its shareholders best interest to merge with DiamiR On June 2, 2025, we entered into the Letter of Intent with DiamiR
for the acquisition of 100% of the outstanding shares of DiamiR for consideration in shares.

Pursuant to the Letter of Intent, we entered into the Merger Agreement
on July 14, 2025, where the Company will acquire 100% of DiamiR outstanding shares of common stock with consideration to be paid in shares
at the closing (the “DiamiR Closing”). Upon consummation of DiamiR Merger, DiamiR will become a wholly-owned subsidiary of
the Company, and the existing DiamiR stockholders and existing Company shareholders will own approximately 70% and 30%, respectively,
of the outstanding shares of the combined company. Pursuant to the Letter of Intent, the Company entered into a licensing agreement
and management agreement with DiamiR concurrently with the Merger Agreement. The closing of the DiamiR Merger will be subject to customary
closing conditions, including the preparation and receipt of certain audited financials and obtaining shareholder approval of the DiamiR
Merger. Therefore, there is no guarantee that such a transaction will occur.

DiamiR is a molecular diagnostics company focused on developing and
commercializing blood-based biomarkers and tests for detection and monitoring of neurodegenerative diseases, such as Mild Cognitive Impairment
(MCI), Alzheimer’s (AD), and Parkinson’ (PD); rare neurodevelopmental conditions, such as Rett Syndrome; and other disorders,
such as cancer and inflammation related diseases. The proprietary technology is based on quantitative analysis of “organ-enriched”,
i.e. present at higher concentration in specific organs or tissues, microRNAs (miRNAs) in plasma. The tests being developed are currently
not commercially available. While launching lab-developed tests (LDT) is DiamiR’s primary goal, by providing testing services for
pharma and biotech companies involved in drug development has allowed it to generate revenues prior to launching the LDTs in the clinical
setting, improve its test performance characteristics, and potentially allow it to offer companion diagnostic solutions to be used alongside